| http://purl.uniprot.org/citations/29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/29693185 | http://www.w3.org/2000/01/rdf-schema#comment | "Breast cancer is the leading cause of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancer cases and has a poorer prognosis than other subtypes. Moreover, the treatment for breast cancer, especially for TNBC, remains unsatisfactory. Therefore, novel therapies are urgently needed. Microribonucleic acids (miRNAs) are a class of biomarkers and therapeutic targets in many types of cancers. In the present study, the expression of miR-384 was explored in GSE58606 and in fresh breast cancer tissues by qPCR. The results showed that miR-384 was decreased in breast cancer, especially in TNBC. The results of MTT, colony formation, soft agar, Transwell migration, wound healing and the tumorigenesis assay demonstranted that overexpression of miR-384 inhibited the proliferation and migration of breast cancer in vitro and in vivo; knockdown of miR-384 enhanced the proliferation and migration of breast cancer. In addition, luciferase assay showed that Activin A receptor type 1 (ACVR1) was a direct target of miR-384 and is involved in the inhibitory effects of miR-384 on breast cancer progression. Furthermore, this study indicated that ACVR1 activated the Wnt/β-catenin signaling pathway in breast cancer. In conclusion, our findings revealed functional and mechanistic links between miR-384 and ACVR1 in the progression of breast cancer. miR-384 not only plays an important role in the progression of breast cancer, but has promise as a potential therapeutic target for breast cancer especially for TNBC."xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.org/dc/terms/identifier | "doi:10.3892/or.2018.6385"xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/author | "Wang Y."xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/author | "Wang J."xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/author | "Zhang Z."xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/date | "2018"xsd:gYear |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/name | "Oncol Rep"xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/pages | "2563-2574"xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/title | "MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1."xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://purl.uniprot.org/core/volume | "39"xsd:string |
| http://purl.uniprot.org/citations/29693185 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/29693185 |
| http://purl.uniprot.org/citations/29693185 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/29693185 |
| http://purl.uniprot.org/uniprot/#_A0A0S2Z2Y3-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_A0A0S2Z345-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_A0A0B5HR54-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_B4DN51-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_D3DPA4-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_Q53SF4-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_Q53SV1-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/#_Q04771-mappedCitation-29693185 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/B4DN51 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/D3DPA4 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/Q04771 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29693185 |
| http://purl.uniprot.org/uniprot/A0A0S2Z345 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/29693185 |